AbbVie, along with EA Pharma, a subsidiary of Japanese pharmaceutical company Eisai, will begin the co-promotion of fully human anti-TNF-alpha monoclonal antibody Humira for indications in the field of gastrointestinal diseases.
Humira is a fully human, anti-tumour necrosis factors (TNF)-alpha monoclonal antibody.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
EA Pharma was established in April this year through the integration of Eisai’s gastrointestinal disease business, and along with Ajinamoto Pharmaceuticals, is a gastrointestinal specialty pharmaceutical firm with a full value chain including research and development, production and logistics, and sales and marketing.
Eisai has assigned the responsibility to EA Pharma to undertake co-promotion on gastrointestinal disease indications for Humira with Abbvie.
There will be no change to the distribution and sales framework for Humira, as AbbVie will continue to be the marketing and manufacturing authorisation holder for Humira, while Eisai is responsible for its distribution.
AbbVie and Eisai will continue the co-promotion for Humira of indications outside of the gastrointestinal disease field such as the treatment of rheumatoid arthritis, including prevention of structural joint damage.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHumira will also be used for diseases that do not sufficiently respond to existing treatments.
The diseases include psoriasis vulgaris, arthropathic psoriasis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis.
The three companies will continue to promote and provide data on the proper use of Humira, while making further contributions to improve the patients’ quality of life.
